AbbVie Reported GAAP & Adjusted Non-GAAP Earnings For Q3 Expected To Include Acquired IPR&D & Milestones Expense Of $82M On Pre-Tax Basis; FY Adj EPS Guidance Range, Including Impact Of Q3 2024 Acquired IPR&D And Milestones Expense, Is $10.67-$10.87; IPR&D & Milestones Expense Representing Unfavorable Impact Of $0.04 To Both GAAP Diluted Eps & Adj Non-GAAP Diluted EPS For Q3
Portfolio Pulse from Benzinga Newsdesk
AbbVie reported its Q3 earnings, including an $82M expense for acquired IPR&D and milestones, impacting both GAAP and adjusted EPS by $0.04. The FY adjusted EPS guidance is set between $10.67 and $10.87.
October 03, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Q3 earnings report includes an $82M expense for acquired IPR&D and milestones, affecting both GAAP and adjusted EPS by $0.04. The full-year adjusted EPS guidance is between $10.67 and $10.87.
The $82M expense for acquired IPR&D and milestones negatively impacts both GAAP and adjusted EPS by $0.04, which could lead to a short-term negative reaction in the stock price. However, the full-year adjusted EPS guidance remains strong, which may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100